430 related articles for article (PubMed ID: 34168333)
1. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC.
Grant MJ; Herbst RS; Goldberg SB
Nat Rev Clin Oncol; 2021 Oct; 18(10):625-644. PubMed ID: 34168333
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
Yoneda K; Imanishi N; Ichiki Y; Tanaka F
J UOEH; 2018; 40(2):173-189. PubMed ID: 29925736
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
4. The next generation of immunotherapy: keeping lung cancer in check.
Somasundaram A; Burns TF
J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
[TBL] [Abstract][Full Text] [Related]
5. Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?
Qiao M; Jiang T; Ren S; Zhou C
Clin Lung Cancer; 2018 Jan; 19(1):1-11. PubMed ID: 28716463
[TBL] [Abstract][Full Text] [Related]
6. Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
Sui H; Ma N; Wang Y; Li H; Liu X; Su Y; Yang J
J Immunol Res; 2018; 2018():6984948. PubMed ID: 30159341
[TBL] [Abstract][Full Text] [Related]
7. Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.
Tanaka I; Morise M
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008669
[TBL] [Abstract][Full Text] [Related]
8. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
Sgambato A; Casaluce F; Gridelli C
Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
[TBL] [Abstract][Full Text] [Related]
9. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
10. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
[TBL] [Abstract][Full Text] [Related]
11. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity.
Rossi S; Castello A; Toschi L; Lopci E
Immunotherapy; 2018 Jul; 10(9):797-805. PubMed ID: 30008262
[TBL] [Abstract][Full Text] [Related]
13. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
[TBL] [Abstract][Full Text] [Related]
14. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.
Proto C; Ferrara R; Signorelli D; Lo Russo G; Galli G; Imbimbo M; Prelaj A; Zilembo N; Ganzinelli M; Pallavicini LM; De Simone I; Colombo MP; Sica A; Torri V; Garassino MC
Cancer Treat Rev; 2019 May; 75():39-51. PubMed ID: 30954906
[TBL] [Abstract][Full Text] [Related]
15. Emerging biomarkers for immune checkpoint inhibition in lung cancer.
Cyriac G; Gandhi L
Semin Cancer Biol; 2018 Oct; 52(Pt 2):269-277. PubMed ID: 29782924
[TBL] [Abstract][Full Text] [Related]
16. [Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer].
Wang S; Li J
Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):682-686. PubMed ID: 27760599
[TBL] [Abstract][Full Text] [Related]
17. New Immunotherapy and Lung Cancer.
Sánchez de Cos Escuín J
Arch Bronconeumol; 2017 Dec; 53(12):682-687. PubMed ID: 28823733
[TBL] [Abstract][Full Text] [Related]
18. The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer.
Zhang S; Bai X; Shan F
Int Immunopharmacol; 2020 Mar; 80():106247. PubMed ID: 32007710
[TBL] [Abstract][Full Text] [Related]
19. Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer.
Pabani A; Butts CA
Curr Oncol; 2018 Jun; 25(Suppl 1):S94-S102. PubMed ID: 29910652
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Blockade for Advanced NSCLC: A New Landscape for Elderly Patients.
Perrotta F; Rocco D; Vitiello F; De Palma R; Guerra G; De Luca A; Navani N; Bianco A
Int J Mol Sci; 2019 May; 20(9):. PubMed ID: 31067796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
